![]() |
|
#1
|
|||
|
|||
|
The pill, called Xofluza, was discovered by Osaka-based Shionogi 4507, -2.70% *and it was approved last year by regulators in Japan and the U.S. In the U.S., it is marketed by Roche Holding AG’s RHHBY, +1.66% * Genentech unit. The drug quickly gained the top share in Japan, according to Shionogi’s data, in part because of its ease of use. Roche’s Tamiflu, the best-known competitor, is generally taken twice a day for five days, while Xofluza is taken just once. A small number of patients report side effects such as diarrhea and bronchitis, according to Genentech. The drug is still relatively little-used in the U.S., where the list price is $150 for patients without insurance. It was the first anti-flu medication approved in the U.S. in nearly 20 years. An expanded version of this report appears on WSJ.com. Popular on WSJ.com: Tesla is cranking out Model 3s—now it has to service them <a href="https://www.wsj.com/articles/tesla-is-cranking-out-model-3snow-it-has-to-service-them-11549810800?mod=trending_now_2" target="_new" class="icon "/> It’s the real world—with Google maps layered on top Want news about Asia delivered to your inbox? Subscribe to MarketWatch’s free Asia Daily newsletter. Sign up here. </p> Source link More ??????? ??????: ‘Miracle’ 24-hour flu pill Xofluza foiled by resistant strains || ??????: ahlam1399 || ??????: اسم منتداك
|
![]() |
|
|